Interactions between levetiracetam and cardiovascular drugs against electroconvulsions in mice

Łukawski, Krzysztof; Raszewski, Grzegorz; Czuczwar, Stanisław J.

doi:10.1016/j.pharep.2014.07.008

Cited by 8 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Losartan (50 mg/kg), candesartan (8 mg/kg), captopril (50 mg/kg) and perindopril (10 mg/kg) were used at doses that did not effectively change the threshold for electroconvulsions [7,8,9] and do not cause adverse effects in the passive avoidance and chimney tests [9]. Both AT 1 receptor antagonists and ACE inhibitors used at these subthreshold doses did not affect the anticonvulsant action of pregabalin in the MES test (Fig.…”

Section: Resultsmentioning

confidence: 98%

“…In the MES test, losartan, an AT 1 receptor antagonist, enhanced the anticonvulsant action of valproate [7]. Captopril, an ACE inhibitor, increased the protective action of carbamazepine and lamotrigine [8], and perindopril (also an ACE inhibitor), potentiated the anticonvulsant activity of levetiracetam [9] against MES-induced convulsions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the combined treatment with pregabalin and inhibitors of the renin-angiotensin system against maximal electroshock in mice

Łukawski¹,

Raszewski²,

Czuczwar³

2018

J Pre Clin Clin Res.

Self Cite

View full text Add to dashboard Cite

Łukawski K, Raszewski G, Czuczwar S. J. Evaluation of the combined treatment with pregabalin and inhibitors of the renin-angiotensin system against maximal electroshock in mice. J Pre-Clin Clin Res. 2018; 12(2): 63-66. doi: 10.26444/jpccr/91611 Abstract Introduction and objective. Hypertension is a common comorbid condition in patients with epilepsy. Combined treatment with antiepileptic drugs (AEDs) and antihypertensives may lead to pharmacokinetic and/or pharmacodynamic interactions. The purpose of the current study was to examine the effects of angiotensin-converting enzyme (ACE) inhibitors (captopril and perindopril) and angiotensin AT 1 receptor antagonists (losartan and candesartan) on the anticonvulsant activity of pregabalin in the maximal electroshock seizure (MES) test in mice. Materials and method. The study was conducted on adult Swiss mice. Drugs were administered intraperitoneally. Electroconvulsions (50 Hz, 500 V, current intensity 25 mA) were produced by a Hugo Sachs generator. Additionally, adverse effects of the combined treatment were assessed in the step-through passive avoidance task and the chimney test. Results. Captopril (50 mg/kg), perindopril (10 mg/kg), losartan (50 mg/kg) and candesartan (8 mg/kg) did not affect the anticonvulsant action of pregabalin in the MES test. In the chimney test, the combinations of pregabalin (315.7 mg/kg) with losartan (50 and 25 mg/kg) significantly impaired motor coordination in mice, P<0.001 and P<0.05, respectively. Combinations of pregabalin with other antihypertensives were ineffective in this test. In the passive avoidance task, co-administration of pregabalin with antihypertensives showed a strong tendency towards impaired retention. Conclusions. It is suggested that the use of pregabalin with the examined antihypertensive drugs in patients with epilepsy is presumed neutral regarding anticonvulsant action of pregabalin. However, caution is advised during co-administration of pregabalin with losartan at high doses due to neurotoxicity in mice.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Evaluation of the combined treatment with pregabalin and inhibitors of the renin-angiotensin system against maximal electroshock in mice

Łukawski¹,

Raszewski²,

Czuczwar³

2018

J Pre Clin Clin Res.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The positive interaction of antihypertensive drugs, including ARBs, ACEi and diuretics, was tested in combination with AED levetiracetam in a MES so as to investigate their synergistic effects in better epilepsy management. In this study, only perindopril arginate positively influenced the pharmacodynamic properties of the antiepileptics [116]. However, in a related study, the ACEi (zofenopril, fosinopril, enalapril, and captopril) was shown to have added pharmacodynamic effects on AEDs (carbamazepine, felbamate, felbamate, lamotrigine, topiramate, and valproate) in animal models with a generalized tonic–clonic seizure.…”

Section: Antiepileptic and Ras Inhibition Drugsmentioning

confidence: 86%

Role of the Angiotensin Pathway and its Target Therapy in Epilepsy Management

Krasniqi

Daci

2019

IJMS

View full text Add to dashboard Cite

Despite extensive research on epileptogenesis, there is still a need to investigate new pathways and targeted therapeutic approaches in this complex process. Inflammation, oxidative stress, neurotoxicity, neural cell death, gliosis, and blood–brain barrier (BBB) dysfunction are the most common causes of epileptogenesis. Moreover, the renin–angiotensin system (RAS) affects the brain’s physiological and pathological conditions, including epilepsy and its consequences. While there are a variety of available pharmacotherapeutic approaches, information on new pathways is in high demand and the achievement of treatment goals is greatly desired. Therefore, targeting the RAS presents an interesting opportunity to better understand this process. This has been supported by preclinical studies, primarily based on RAS enzyme, receptor-inhibition, and selective agonists, which are characterized by pleiotropic properties. Although there are some antiepileptic drugs (AEDs) that interfere with RAS, the main targeted therapy of this pathway contributes in synergy with AEDs. However, the RAS-targeted treatment alone, or in combination with AEDs, requires clinical studies to contribute to, and clarify, the evidence on epilepsy management. There is also a genetic association between RAS and epilepsy, and an involvement of pharmacogenetics in RAS, so there are possibilities for the development of new diagnostic and personalized treatments for epilepsy.

show abstract

“…In the mouse maximal electroshock-induced seizure model, FBM increased LEV concentration in the brain, leading to an additive anticonvulsant effect [153]. It was shown that perindopril arginine may positively influence the pharmacological action of LEV in epileptic patients [154].…”

Section: Piracetam and Its Newer Derivativesmentioning

confidence: 99%

Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients

Karaźniewicz−Łada

Główka

Mikulska

et al. 2021

IJMS

View full text Add to dashboard Cite

Anti-epileptic drugs (AEDs) are an important group of drugs of several generations, ranging from the oldest phenobarbital (1912) to the most recent cenobamate (2019). Cannabidiol (CBD) is increasingly used to treat epilepsy. The outbreak of the SARS-CoV-2 pandemic in 2019 created new challenges in the effective treatment of epilepsy in COVID-19 patients. The purpose of this review is to present data from the last few years on drug–drug interactions among of AEDs, as well as AEDs with other drugs, nutrients and food. Literature data was collected mainly in PubMed, as well as google base. The most important pharmacokinetic parameters of the chosen 29 AEDs, mechanism of action and clinical application, as well as their biotransformation, are presented. We pay a special attention to the new potential interactions of the applied first-generation AEDs (carbamazepine, oxcarbazepine, phenytoin, phenobarbital and primidone), on decreased concentration of some medications (atazanavir and remdesivir), or their compositions (darunavir/cobicistat and lopinavir/ritonavir) used in the treatment of COVID-19 patients. CBD interactions with AEDs are clearly defined. In addition, nutrients, as well as diet, cause changes in pharmacokinetics of some AEDs. The understanding of the pharmacokinetic interactions of the AEDs seems to be important in effective management of epilepsy.

show abstract

Interactions between levetiracetam and cardiovascular drugs against electroconvulsions in mice

Cited by 8 publications

References 43 publications

Evaluation of the combined treatment with pregabalin and inhibitors of the renin-angiotensin system against maximal electroshock in mice

Evaluation of the combined treatment with pregabalin and inhibitors of the renin-angiotensin system against maximal electroshock in mice

Role of the Angiotensin Pathway and its Target Therapy in Epilepsy Management

Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients

Contact Info

Product

Resources

About